Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.76% |
| 2 | Technology | 16.41% |
| 3 | Consumer Staples | 10.58% |
| 4 | Consumer Discretionary | 10.12% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3176
Solitario Resources
XPL
$54M
| $189K | ﹤0.01% |
600,416
+183,386
| +44% | +$49.6K |
2015 Q4
18 quarters
|
|
3177
HBT Financial
HBT
$1.27B
| $188K | ﹤0.01% |
+14,100
| New | +$169K |
2020 Q2
0 quarters
|
|
3178
Peraso
PRSO
$6.06M
| $188K | ﹤0.01% |
2,569
-43
| -2% | -$2.69K |
2018 Q4
6 quarters
|
|
|
REVG
3179
DELISTED
REV Group
REVG
| $188K | ﹤0.01% |
30,800
-7,991
| -21% | -$42.9K |
2019 Q4
2 quarters
|
|
3180
KALA BIO
KALA
$5.68M
| $181K | ﹤0.01% |
7
-40
| -85% | -$1.13M |
2020 Q1
1 quarter
|
|
3181
ClearPoint Neuro
CLPT
$320M
| $180K | ﹤0.01% |
50,600
+22,300
| +79% | +$82.9K |
2020 Q1
1 quarter
|
|
3182
Exicure
XCUR
$6.87M
| $179K | ﹤0.01% |
490
-1,266
| -72% | -$459K |
2020 Q1
1 quarter
|
|
|
CNSY
3183
Cerenome
CNSY
$14.6M
| $178K | ﹤0.01% |
224
+8
| +4% | +$5.34K |
2018 Q2
8 quarters
|
|
|
HZN
3184
DELISTED
Horizon Global Corporation
HZN
| $178K | ﹤0.01% |
81,002
-1,900
| -2% | -$3.48K |
2019 Q3
3 quarters
|
|
|
SSY
3185
DELISTED
SunLink Health Systems
SSY
| $177K | ﹤0.01% |
197,800
+30,400
| +18% | +$23.9K |
2014 Q1
25 quarters
|
|
3186
Xenetic Biosciences
XBIO
$4.99M
| $177K | ﹤0.01% |
17,320
+908
| +6% | +$8.62K |
2019 Q4
2 quarters
|
|
|
IMMP
3187
Immutep
IMMP
$26.7M
| $176K | ﹤0.01% |
8,132
-8,732
| -52% | -$180K |
2018 Q3
7 quarters
|
|
|
TWAV
3188
TaoWeave Inc
TWAV
$5.7M
| $176K | ﹤0.01% |
197
+67
| +52% | +$46.7K |
2019 Q2
4 quarters
|
|
|
EVLO
3189
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
| $176K | ﹤0.01% |
1,799
+420
| +30% | +$36.8K |
2019 Q3
3 quarters
|
|
3190
Oragenics
OGEN
$2.06M
| $174K | ﹤0.01% |
+139
| New | +$137K |
2020 Q2
0 quarters
|
|
|
OSN
3191
DELISTED
Ossen Innovation Co., Ltd.
OSN
| $173K | ﹤0.01% |
61,589
-15,317
| -20% | -$33.7K |
2019 Q3
3 quarters
|
|
|
ASXC
3192
DELISTED
Asensus Surgical, Inc.
ASXC
| $172K | ﹤0.01% |
+318,467
| New | +$154K |
2020 Q2
0 quarters
|
|
|
VVUS
3193
DELISTED
Vivus Inc
VVUS
| $169K | ﹤0.01% |
205,341
-211,804
| -51% | -$251K |
2015 Q2
20 quarters
|
|
|
CRESY
3194
Cresud
CRESY
$810M
| $168K | ﹤0.01% |
+59,006
| New | +$189K |
2020 Q2
0 quarters
|
|
3195
Alaunos Therapeutics
TCRT
$2M
| $167K | ﹤0.01% |
338
-4,176
| -93% | -$1.86M |
2019 Q2
4 quarters
|
|
|
IRS
3196
IRSA Inversiones y Representaciones
IRS
$1.16B
| $166K | ﹤0.01% |
+53,025
| New | +$183K |
2020 Q2
0 quarters
|
|
|
BKYI
3197
BIO-key International
BKYI
$2.4M
| $164K | ﹤0.01% |
+128
| New | +$152K |
2020 Q2
0 quarters
|
|
|
BCOM
3198
DELISTED
B Communications Ltd
BCOM
| $164K | ﹤0.01% |
82,466
+14,450
| +21% | +$21.7K |
2013 Q3
27 quarters
|
|
3199
Phio Pharmaceuticals
PHIO
$11.4M
| $162K | ﹤0.01% |
687
+306
| +80% | +$73.3K |
2019 Q1
5 quarters
|
|
|
THER
3200
DELISTED
THERATECHNOLOGIES INC COM
THER
| $161K | ﹤0.01% |
80,300
+29,300
| +57% | +$58.7K |
2019 Q4
2 quarters
|
|
Similar funds
Renaissance Technologies's Q2 2020 Portfolio in Review
As of Q2 2020, Renaissance Technologies held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Renaissance Technologies withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,365 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 26% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Renaissance Technologies opened a new position in Uber worth $187M.
- Renaissance Technologies's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Renaissance Technologies added most to Zoom in Q2 2020, an estimated $806M increase.
- Renaissance Technologies's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Renaissance Technologies fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Renaissance Technologies's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Renaissance Technologies opened 584 new positions and closed 596 in Q2 2020.
- Renaissance Technologies's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.